Eli Lilly’s New Weight-Loss Drug Receives U.K. Marketing Authorization, Securing Another Milestone in European Market Expansion

Life Science

Anthropic Locks In Riot Data Center Capacity with $9.1 Billion Deal

Cryptocurrency, Life Science, Technology

AbCellera Soars Nearly 40% as Menopause Drug Data ‘Wows’ Analysts

Life Science

Unpacking the Investment Value of AbbVie and Abbott in 2026

Life Science

Eli Lilly Locks In Retatrutide FDA Filing Date — Can the Stock Climb to $1,750 by 2027?

Life Science

The Diversification Illusion: Don’t Be Fooled by S&P 500 Sector ETFs

Consumer Goods, Energy, Financial Service, Life Science, Real Estate, Technology

Down 46%, Yet Wall Street Predicts a 161% Surge: Would You Bet on This Weight-Loss Drug Stock?

Life Science

Lilly’s Q2 Smashes Estimates, Yet the Stock Barely Budges in 2026

Life Science

5 High-Dividend Value Stocks to Buy as Market Valuations Stretch to Extremes

Consumer Goods, Life Science, Real Estate, Technology

Medtronic Could Rally 40% by Year-End, With Dividend King Status on the Horizon

Life Science

Vertex Tops Q2 Estimates, But Investors Shift Focus to Crinetics Deal Integration

Life Science

AbbVie Lowers Full-Year Profit Guidance, Investor Disappointment Triggers Stock Sell-Off

Life Science

Novo Nordisk: At 11x P/E, a Golden Entry or a Value Trap?

Life Science

Bristol-Myers Squibb Beats Estimates in Q2, Stock Outperforms Market on Thursday

Life Science

Weight-Loss Pipeline in Focus: Viking Therapeutics Could Be the Next Acquisition Target

Life Science